# Biocad clinical trials: 94 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 94 trials with Biocad as lead sponsor, 11 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Biocad: 94 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/biocad

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 94
- Recruiting or not yet: 11
- Read on: November 19, 2026

## Trials

The 25 newest of 94, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 3, 2026 | NCT07742215 | A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma... | Biocad | Phase 3 | Recruiting | Myeloma Multiple | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742215) |
| January 6, 2026 | NCT07321093 | A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis | Biocad | Phase 3 | Recruiting | Relapsing-remitting Multiple Sclerosis (RRMS) | 292 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07321093) |
| September 18, 2025 | NCT07181694 | A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects | Biocad | Phase 1 | Completed | Healthy Adult Male | 444 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07181694) |
| August 22, 2025 | NCT07136389 | Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus | Biocad | Phase 1 | Recruiting | Systemic Lupus Erthematosus | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07136389) |
| August 13, 2025 | NCT07119372 | Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis | Biocad | Phase 3 | Active not recruiting | Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis, Chronic Kidney Disease 5D | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07119372) |
| August 7, 2025 | NCT07108309 | BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer | Biocad | Phase 2 | Recruiting | Triple Negative Breast Cancer | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07108309) |
| July 23, 2025 | NCT07080034 | Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active... | Biocad | Phase 2 | Recruiting | Ulcerative Colitis (UC) | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07080034) |
| July 22, 2025 | NCT07078994 | Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to... | Biocad | Phase 2 | Recruiting | Crohn's Disease (CD) | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07078994) |
| May 23, 2025 | NCT06987864 | An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN | Biocad | Phase 3 | Completed | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06987864) |
| May 23, 2025 | NCT06987851 | An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in... | Biocad | Phase 3 | Completed | Multiple Sclerosis | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06987851) |
| December 4, 2024 | NCT06715540 | Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects | Biocad | Phase 1 | Recruiting | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06715540) |
| November 21, 2024 | NCT06700096 | An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B | Biocad | Phase 3 | Recruiting | Hemophilia B | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06700096) |
| October 31, 2024 | NCT06668792 | An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma | Biocad | Phase 2 | Recruiting | Relapsed/Refractory Multiple Myeloma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06668792) |
| October 15, 2024 | NCT06640530 | Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | Biocad | Phase 3 | Active not recruiting | Advanced Melanoma, Melanoma (Skin) | 392 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06640530) |
| October 15, 2024 | NCT06640517 | Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis | Biocad | Phase 3 | Active not recruiting | Plaque Psoriasis | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06640517) |
| March 27, 2024 | NCT06333210 | Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA) | Biocad | Phase 3 | Active not recruiting | Axial Spondyloarthritis | 421 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06333210) |
| March 6, 2024 | NCT06296121 | A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma | Biocad | Phase 3 | Unknown | Multiple Myeloma | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06296121) |
| December 29, 2023 | NCT06185335 | A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A | Biocad | Phase 1/2 | Active not recruiting | Hemophilia A | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06185335) |
| November 7, 2023 | NCT06120582 | Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN) | Biocad | Phase 1/2 | Recruiting | Hemophilia B | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06120582) |
| November 2, 2023 | NCT06112808 | A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | Biocad | Phase 1 | Active not recruiting | Advanced Melanoma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06112808) |
| August 14, 2023 | NCT05986331 | Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma | Biocad | Phase 3 | Unknown | Melanoma (Skin) | 366 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05986331) |
| August 3, 2023 | NCT05974969 | A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects | Biocad | Phase 1 | Completed | Healthy | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05974969) |
| April 6, 2023 | NCT05802225 | Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer | Biocad | Phase 3 | Active not recruiting | Breast Cancer | 398 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05802225) |
| April 5, 2023 | NCT05800327 | A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When... | Biocad | Phase 3 | Active not recruiting | Rheumatoid Arthritis | 261 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05800327) |
| March 24, 2023 | NCT05783882 | Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma | Biocad | Phase 3 | Unknown | Unresectable or Metastatic Melanoma | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05783882) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 28 |
| Phase 1/2 | 4 |
| Phase 2 | 15 |
| Phase 2/3 | 4 |
| Phase 3 | 42 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 51 |
| Unknown | 15 |
| Active not recruiting | 13 |
| Recruiting | 11 |
| Terminated | 2 |
| Withdrawn | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Melanoma | 11 |
| Multiple Sclerosis | 6 |
| Breast Neoplasms | 6 |
| Arthritis, Rheumatoid | 5 |
| Spondylitis, Ankylosing | 4 |
| Anemia | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Multiple Sclerosis, Relapsing-Remitting | 3 |
| Hepatitis | 3 |
| Hepatitis C | 3 |
| Multiple Myeloma | 3 |
| Psoriasis | 2 |
| Renal Insufficiency, Chronic | 2 |
| Diabetes Mellitus, Insulin-Dependent, 12 | 2 |
| Colitis, Ulcerative | 2 |
| Hemoglobinuria, Paroxysmal | 2 |
| COVID-19 | 2 |
| Crohn Disease | 2 |
| Neutropenia | 2 |
| Febrile Neutropenia | 2 |
| Uterine Cervical Neoplasms | 2 |
| Hemophilia B | 2 |
| Axial Spondyloarthritis | 2 |
| Carcinoma, Renal Cell | 2 |
| Lymphoma, Follicular | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Basque restaurants in the United States](https://specstream.ai/data/businesses/basque-restaurants/united-states)
- [Valet services in the United States](https://specstream.ai/data/businesses/valet-services/united-states)
- [Public utilities in the United States](https://specstream.ai/data/businesses/public-utilities/united-states)
- [Mattress manufacturing companies in the United States](https://specstream.ai/data/businesses/mattress-manufacturing-companies/united-states)
- [Gardening services in the United States](https://specstream.ai/data/businesses/gardening-services/united-states)
- [Computer training centers in the United States](https://specstream.ai/data/businesses/computer-training-centers/united-states)
